Evidence map›Paper›PMID 31509233›Full record

ArticleJournal of the American Geriatrics Society2020

Physician Perspectives on Deprescribing Cardiovascular Medications for Older Adults.

Parag Goyal, Timothy S Anderson, Gwen M Bernacki, Zachary A Marcum, Ariela R Orkaby, Dae Kim, Andrew Zullo, Ashok Krishnaswami, Arlene Weissman, Michael A Steinman and 1 more

Open access · greenAbstract read
In one paragraph

Article in Journal of the American Geriatrics Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 2 pooled it
6.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 2 syntheses or guidelines pooled it, 93 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Trial
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Pharmacy (Basel, Switzerland) · 2025
    Article
  11. Review
  12. A National Physician Survey Examining Switching From Sulfonylureas or Insulin to Newer Diabetes Medications.Clinical diabetes : a publication of the American Diabetes Association · 2025
    Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 9 institutions in 2 countries.

Parag GoyalDepartment of Medicine, Weill Cornell Medicine, New York, New York.ORCID 0000-0001-7474-3737
Timothy S AndersonDivision of General Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts.ORCID 0000-0002-5384-275X
Gwen M BernackiCardiology Division, University of Washington, Seattle, Washington.
Zachary A MarcumDepartment of Pharmacy, University of Washington, Seattle, Washington.ORCID 0000-0002-4690-2304
Ariela R OrkabyNew England Geriatric Research, Education, and Clinical Center, Veterans Affairs (VA) Boston Healthcare System, Boston, Massachusetts.
Dae KimMarcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0001-7290-6838
Andrew ZulloDepartment of Epidemiology and Health Services, Policy, and Practice, Brown University School of Public Health, Providence, Rhode Island.ORCID 0000-0003-1673-4570
Ashok KrishnaswamiDivision of Cardiology, Kaiser Permanente San Jose Medical Center, San Jose, California.
Arlene WeissmanDivision of Geriatrics, San Francisca Veterans Affairs Medical Center, San Francisco, California.
Michael A SteinmanSan Francisco Veterans Affairs Medical Center, San Francisco, California.
Michael W RichCardiovascular Division, Washington University School of Medicine, St Louis, Missouri.
San Francisco VA Medical Center · USUniversity of Washington · USBeth Israel Deaconess Medical Center · USBrigham and Women's Hospital · USCornell University · USHarvard University · USRhode Island Department of Health · USUniversity of California, San Francisco · USWashington University in St. Louis · US

Funding

VARC CoreP30AG044281 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Louise C. Walter · 2013 to 2026
$19.9M
U.S. Deprescribing Research NetworkR24AG064025 · NIA · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI BOYD, CYNTHIA MELINDA, STEINMAN, MICHAEL A. · 2019 to 2023
$9.9M
Prescribing cascades in older adults with and without dementiaK24AG049057 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEINMAN, MICHAEL A. · 2015 to 2025
$1.8M
Antihypertensives and the Aging BrainK76AG059929 · NIA · UNIVERSITY OF WASHINGTON · PI MARCUM, ZACHARY ADAM · 2019 to 2021
$694k
Impact of Intensive Blood Pressure Treatment on Clinical Outcomes of Hospitalized Older AdultsR03AG064373 · NIA · BETH ISRAEL DEACONESS MEDICAL CENTER · PI ANDERSON, TIMOTHY S · 2019 to 2020
$274k
Impact of Polypharmacy on Rehospitalization in Older Adults with Heart FailureR03AG056446 · NIA · WEILL MEDICAL COLL OF CORNELL UNIV · PI GOYAL, PARAG · 2017 to 2018
$265k
Integration of Geriatrics Principles into the Care of Older Adults with CardiovasU13AG047008 · NIA · AMERICAN COLLEGE OF CARDIOLOGY · PI RICH, MICHAEL W · 2014 to 2018
$210k
Frailty, Statins, and Cardiovascular Disease Burden in Older AdultsR03AG060169 · NIA · HARVARD MEDICAL SCHOOL · PI ORKABY, ARIELA R · 2018 to 2019
$193k
AHRQ HHS K12 HS022982CSRD VA IK2 CX001800NIA NIH HHS K24 AG049057NIA NIH HHS K76 AG059929NIA NIH HHS L30 AG060493NIA NIH HHS L30 AG060521NIA NIH HHS P30 AG044281NIA NIH HHS R03 AG056446NIA NIH HHS R03 AG060169NIA NIH HHS R03 AG064373NIA NIH HHS R24 AG064025NIA NIH HHS U13 AG047008
6 · The paper itself

Abstract

BACKGROUND/

objectivesGuideline-based management of cardiovascular disease often involves prescribing multiple medications, which contributes to polypharmacy and risk for adverse drug events in older adults. Deprescribing is a potential strategy to mitigate these risks. We sought to characterize and compare clinician perspectives regarding deprescribing cardiovascular medications across three specialties.

designNational cross-sectional survey.

settingAmbulatory.

participantsRandom sample of geriatricians, general internists, and cardiologists from the American College of Physicians. MEASUREMENTS: Electronic survey assessing clinical practice of deprescribing cardiovascular medications, reasons and barriers to deprescribing, and choice of medications to deprescribe in hypothetical clinical cases.

resultsIn each specialty, 750 physicians were surveyed, with a response rate of 26% for geriatricians, 26% for general internists, and 12% for cardiologists. Over 80% of respondents within each specialty reported that they had recently considered deprescribing a cardiovascular medication. Adverse drug reactions were the most common reason for deprescribing for all specialties. Geriatricians also commonly reported deprescribing in the setting of limited life expectancy. Barriers to deprescribing were shared across specialties and included concerns about interfering with other physicians' treatment plans and patient reluctance. In hypothetical cases, over 90% of physicians in each specialty chose to deprescribe when patients experienced adverse drug reactions. Geriatricians were most likely and cardiologists were least likely to consider deprescribing cardiovascular medications in cases of limited life expectancy (all P < .001), such as recurrent metastatic cancer (84% of geriatricians, 68% of general internists, and 45% of cardiologists), Alzheimer dementia (92% of geriatricians, 81% of general internists, and 59% of cardiologists), or significant functional impairment (83% of geriatricians, 68% of general internists, and 45% of cardiologists).

conclusionsWhile barriers to deprescribing cardiovascular medications are shared across specialties, reasons for deprescribing, especially in the setting of limited life expectancy, varied. Implementing deprescribing will require improved processes for both physician-physician and physician-patient communication. J Am Geriatr Soc 68:78-86, 2019.

Indexed as

DeprescriptionsDrug-Related Side Effects and Adverse ReactionsLife ExpectancyAgedCardiologistsCardiovascular AgentsCardiovascular DiseasesChronic DiseaseCross-Sectional StudiesFemaleFrail ElderlyGeriatriciansHumansMaleSurveys and QuestionnairesUnited StatesCardiovascular Agentscardiovascular medicationsdeprescribingpolypharmacyvariation in care

Identifiers

PMID31509233
PMCPMC7061460
OpenAlexW2972331026

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.